Ken Griffin Immix Biopharma, Inc. Transaction History
Citadel Advisors LLC
- $618 Billion
- Q3 2025
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Immix Biopharma, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 89,798 shares of IMMX stock, worth $378,049. This represents 0.0% of its overall portfolio holdings.
Number of Shares
89,798Holding current value
$378,049% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding IMMX
# of Institutions
34Shares Held
3.15MCall Options Held
0Put Options Held
0-
Bleichroeder LP New York, NY850KShares$3.58 Million0.48% of portfolio
-
Vanguard Group Inc Valley Forge, PA730KShares$3.07 Million0.0% of portfolio
-
Lynwood Capital Management Inc.405KShares$1.71 Million11.13% of portfolio
-
Geode Capital Management, LLC Boston, MA187KShares$789,2730.0% of portfolio
-
Morgan Stanley New York, NY121KShares$508,0200.0% of portfolio
About Immix Biopharma, Inc.
- Ticker IMMX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 13,910,100
- Market Cap $58.6M
- Description
- Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specif...